RE:RE:Current landscape no longer warrants the debt levelShorts can and do distort prices. Mr Wynn can testify! However when we see sustained 70% drop and plenty of shares to buy so "cheap" we can no longer call it "short distort". Up to a 15% on low volume I can see it... past that it must be numbers... company business.... the valuation! There's no private equity fund that would let pass a chance! Hence... forget about "plenty of cashflow". I wanted some numbers worked backwords up to the revenue, and check against current meds prices. This is where sellers, and short sellers might be right. The sellers bank that 2017 will have CXR face solvency... new issue? sell assets? chapter 11?